Stimatix has developed low-profile innovative solutions for colostomy management, intended to improve the quality of life for people with stomas.
In November 2014, Stimatix sold its assets to a subsidiary company of the B. Braun Group, B. Braun Medical SAS. Stimatix is a developer of low-profile innovative solutions for colostomy management, created to improve the quality of life for people with stomas. Trendlines currently maintains a 28.2% holding in Stimatix. As of the last valuation dated 31 December 2017, the fair value of Trendlines’ Stimatix holding, was US$42.6 million. B. Braun have advised Trendlines that their product launch remains on schedule for 2018.
The worldwide stoma/ostomy care market is estimated to reach US$2.99 billion by 2022.* Stimatix represents a very significant achievement for Trendlines. It is a good example of a company that fulfills the Trendlines’ mission of creating and developing companies to improve the human condition as well as creating considerable value for our shareholders.
Read the full announcement (PDF).
Awards: 2011, Best Start-Up, Israel’s Office of the Chief Scientist of the Ministry of Economy
*Markets and Markets, https://www.marketsandmarkets.com/PressReleases/ostomy-care-accessories.asp
Minimally invasive treatment of heart valve disease
A more efficient ablation catheter to treat atrial fibrillation
Preventing the development of pressure sores
Novel treatment for vertebral compression fractures
Preventing catheter-associated urinary tract infections (CAUTIs)
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer